Home/Pipeline/ACI-7104.056 (VacSYn)

ACI-7104.056 (VacSYn)

Parkinson's Disease

Phase 2Active - Positive interim safety & immunogenicity data reported

Key Facts

Indication

Parkinson's Disease

Phase

Phase 2

Status

Active - Positive interim safety & immunogenicity data reported

Company

AC Immune

About AC Immune

AC Immune's mission is to diagnose, treat, and prevent neurodegenerative diseases through a precision medicine approach. The company has achieved significant validation through high-value partnerships with major pharmaceutical firms like Takeda, Janssen, and Lilly, and its pipeline features promising Phase 2 candidates in Alzheimer's and Parkinson's disease. Its strategy balances internal R&D of first- and best-in-class candidates with strategic collaborations that provide non-dilutive funding and de-risk development.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active
golexanolone	Umecrine Cognition	Preclinical	Active
Parkin Activator Program	Progenra	Pre-clinical	Active
Not Specified	Asceneuron	Not Disclosed	Active